Senhwa Biosciences (6492.TWO)

Executive Summary

Senhwa Biosciences is a clinical-stage biotechnology company developing novel small molecule therapeutics targeting DNA Damage Response (DDR) pathways for cancer treatment. Its lead program, Pidnarulex (CX-5461), is a first-in-class inhibitor of RNA Polymerase I transcription currently in Phase I/II trials for solid tumors with BRCA1/2 mutations or other DDR deficiencies. The company also has Silmitasertib (CX-4945), a CK2 inhibitor, in clinical development for cholangiocarcinoma and other indications. With a focus on addressing significant unmet medical needs in oncology, Senhwa aims to provide targeted therapies for patients with limited treatment options. The company is publicly traded on the Taipei Exchange under ticker 6492.TWO and has a market capitalization of approximately $121 million as of mid-2026. Recent efforts have centered on advancing clinical trials for Pidnarulex, including expansion into combination therapies and biomarker-driven patient selection.

Upcoming Catalysts (preview)

• Q3 2026Pidnarulex Phase I/II data update in DDR-deficient tumors40% success
• Q4 2026Silmitasertib Phase II data in cholangiocarcinoma35% success
• TBDPotential partnership or licensing deal for DDR portfolio30% success